Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DKFZ and Bayer: A partnership in drug discovery and development

Prof. Otmar Wiestler, Chairman and Scientific Director of DKFZ (left), and Dr. Wolfgang Plischke, member of the Board of Management of Bayer AG, responsible for Innovation, Technology, and Environment, signing the cooperation agreement

The German Cancer Research Center (DKFZ) and Bayer are collaborating in a strategic alliance in the field of oncologic drug discovery and development since 2008. This cooperation is intended to foster and to expedite translation of research findings into therapeutic development and/or medical applications. To reach this goal, the partners provide dedicated support to projects which are in the transition from basic research to early drug discovery. The cooperation involves shared financing of joint projects: up to 6 million Euros in total per year are provided for such projects. Financial terms, confidentiality issues, management of intellectual property rights and the commercial exploitation of joint findings are covered by a detailed framework agreement. As a consequence, scientists on both sides do not have to worry about these issues, which leaves them free to concentrate on their scientific work. Furthermore, novel project ideas can be picked-up quickly to start a joint project.  In addition, fee-for-service projects, exclusively funded by Bayer, may be initiated.

In 2013, the alliance partners extended their successful collaboration by a joint laboratory. In this lab, the partners work on more advanced projects in the area of immune-oncology (“Joint Immunotherapeutics Lab”). For these projects, the partners jointly invest up to 2.5 Million Euros per year.

To initiate joint translational projects, the partnership also supports the exchange of ideas and promotes personal contacts between DKFZ and Bayer scientists. Mutual visits or joint organisation of scientific events are examples of scientific exchange and dialogue. Once a joint project has been started, the mixed, interdisciplinary teams intensively cooperate in the form of project meetings and joint completion of the project plan. Depending on the project plan, a temporary research stay at Bayer in Berlin or Wuppertal can be envisaged.

The alliance is managed by three joint committees with equal representation of DKFZ and Bayer members. They decide on project selection, funding, and duration of projects. Joint decision making ensures that only those projects are funded that include scientific questions and promises for pharmaceutical development, and as such are interesting for both sides to follow-up.
Up to now, 46 joint projects have been initiated, of which 23 have already reached first milestones in early pharmaceutical development. The most advanced project entered a first clinical trial in July 2016, another project in the area of immunotherapy is planned to enter clinical testing in 2018.

For questions, please contact the DKFZ-Bayer Alliance Manager.

to top
powered by webEdition CMS